AzTrials
AzTrials

Acute AppendicitisAPPACIINCT03236961

Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis

A study testing Ertapenem and Moxifloxacin in people with Acute Appendicitis, run by Turku University Hospital at 1 site in Finland.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Acute Appendicitis
What is being tested?
Ertapenem and Moxifloxacin
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
552 participants
Where
1 siteFinland
Study dates
3 Apr 2017to 1 Apr 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Age 18-60 years
  • CT confirmed uncomplicated acute appendicitis
  • Ability to give consent to participate in the study

Who cannot join

  • Age under 18 years or over 60 years
  • Pregnancy or lactation
  • Allergy to contrast media or iodine
  • Allergy or contraindication to antibiotic therapy
  • Renal insufficiency
  • Metformin medication
Show all 9Show fewer
  • Severe systemic illness (for example malignancy, medical condition requiring immunosuppressant medication)
  • CT confirmed complicated acute appendicitis
  • Inability to co-operate and give informed consent

Trial locations and contacts

1 site in 1 country.

Finland1 site
  • Turku University Hospital

    Turku

Other trials in Finland

About this study

Official title: Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis: a Prospective Randomised Multicenter Study (The APPAC II Study)

Appendicectomy has been the treatment of acute appendicitis for over a hundred years. Appendicectomy, however, includes operative and postoperative risks despite being a routine procedure. Several studies have proved promising results of the safety and efficiency of antibiotics in the treatment of acute uncomplicated appendicitis. The APPAC study by the investigators, published in 2015 in the Journal of American Medical Association, also proved promising results with 73% of patients with uncomplicated appendicitis treated successfully with antibiotics. None of the patients initially treated with antibiotics that later had appendectomy had major complications. The results of the APPAC trial suggest that CT proven uncomplicated acute appendicitis is not a surgical emergency and antibiotic therapy is a safe first-line treatment option. Reducing unnecessary appendectomies has also been shown to lead to significant economic savings.

The aim of this randomized prospective study is to optimize antibiotic therapy for uncomplicated acute appendicitis by comparing different antibiotic regimens; intravenous antibiotic (ertapenem) followed by per oral antibiotic (levofloxacin and metronidazole) with only per oral antibiotics (moxifloxacin). Before randomization, the diagnosis of acute uncomplicated appendicitis is confirmed with a CT scan.

The hypothesis is that broad-spectrum intravenous antibiotics requiring additional hospital resources are not necessary for the treatment of uncomplicated acute appendicitis and that per oral mono therapy is non-inferior to the combination of intravenous and per oral antibiotic therapy.

Read the detailed description

Acute appendicitis is the most common cause of abdominal pain in emergency departments and appendectomy is the most common emergency abdominal surgery. The lifetime risk of acute appendicitis in males is 8.6% and 6.7% in females. In Finland according to Stakes data there were 6 377 appendectomies (3242 in males, 3135 in females, median age 35 years) performed in 2010. The total number of days in hospital care was 16 111 days and the mean length of hospital stay was three days.

Although acute appendicitis is the most common reason for surgical emergency department visit, its diagnosis still remains challenging. The clinical diagnosis has previously been based on patient history, physical examination and laboratory findings as well as the clinical surgical diagnosis. Several scoring systems have been created to aid in the diagnosis of acute appendicitis18-20, but the accuracy of clinical diagnosis without preoperative imaging is about 76 - 80 % for combined patient groups of males and females.

As acute appendicitis has historically been thought to always progress to perforation requiring emergency appendectomy, high negative appendectomy rates even up to 40 % in some patient populations have been previously accepted as good surgical practice. For the last two decades, the use of dedicated imaging in acute abdomen in general and also in acute appendicitis has led to improved diagnostic accuracy.

Based on large epidemiological studies, it is now known that complicated (perforated) and uncomplicated (non-perforated) appendicitis have followed different epidemiological trends. These unassociated epidemiologic trends suggest different pathophysiology for the two form of appendicitis. The differential diagnosis is essential as patients with an uncomplicated acute appendicitis may not require surgical intervention and might experience even spontaneous resolution without perforation. The majority (approximately 80 %) of acute appendicitis cases are of uncomplicated nature.

Complicated acute appendicitis defined as a finding of a perforation, appendicolith, abscess or a suspicion of a tumor, requires emergency appendectomy with the exception of cases with abscess as they are often managed conservatively.

Appendicolith is a calcified fecal concretion in the appendix resulting in internal luminal obstruction and it is the most common form of complicated acute appendicitis. In the first randomized study by Vons et al. comparing operative treatment and antibiotic therapy using CT as a diagnostic inclusion criterion, the presence of an appendicolith in preoperative CT scan was the only factor that significantly increased the risk of complicated appendicitis and it was also the only factor associated with the failure of antibiotic therapy for acute appendicitis. Indeed, if Vons et al had excluded the patients with an appendicolith from their analysis, no significant difference in the incidence of post-intervention peritonitis between the treatment groups would have been noticed in their study.

CT imaging is the primary imaging modality and the golden standard in the diagnosis of acute appendicitis as it establishes the diagnosis with almost perfect diagnostic accuracy. The advantages of CT imaging are high accuracy, availability, ease of performance and interpretation, and that it is rarely affected by bowel gas, severe abdominal pain or extreme body habitus. The main disadvantage of CT is exposure to radiation.

The increased use of preoperative CT imaging has been evaluated thoroughly by evaluating its impact on the negative appendectomy rate reducing the number of unnecessary appendectomies. In 2010, a mandatory imaging guideline for suspected acute appendicitis was implemented in the Netherlands. After implementation the negative appendectomy rate dropped significantly from 23 % to 6 % (p<0.001) reducing the surgical complication rate from 20% to 14 % and resulting in average cost-per-patient decrease by 594€.

The favorable diagnostic performance of CT imaging has encouraged optimization of the protocol to minimize exposure to radiation through the development of low-dose CT protocols. Low-dose protocols balance with as low as reasonably achievable-principle while maintaining diagnostic accuracy. However, low-dose protocols with intravenous contrast are still not implemented in routine clinical practice. These protocols require more advanced optimization and validation because of the wider need for contrast enhanced assessment. Kim et al showed that contrast enhanced low-dose CT (median radiation dose 116mmGy in dose-length product) was not inferior to standard-dose contrast enhanced CT (median radiation dose 521 mmGy), with negative appendectomy rates of 3.5% and 3.2% respectively and no statistical significance in appendiceal perforation rates or patients requiring additional imaging.

The investigators have performed a prospective observational study (OPTICAP trial, NCT02533869, Ethical committee of Turku University Hospital approval) in order to optimize a low-dose CT scan for both diagnosing acute appendicitis and to differentiate uncomplicated acute appendicitis from a complicated acute appendicitis. In this study, phantom imaging with 15 different imaging protocols were performed aiming to minimize radiation with optimal diagnostic accuracy. The phantom protocols were assessed by blinded evaluation of two gastrointestinal radiologists and the two best performing protocols were chosen for the clinical phase. The clinical evaluation included performing both of these imaging protocols for patients with suspected uncomplicated acute appendicitis evaluated by a senior digestive surgeon. All of the enrolled patients underwent laparoscopic appendectomy to evaluate the sensitivity and specificity of the imaging protocols. The most optimal imaging protocols were selected for use in the APPAC II trial; one low-dose CT protocol for patients with BMI under 30 and one optimised standard CT protocol for patients with BMI exceeding 30.

For over a century appendectomy has been the standard treatment for all patients with acute appendicitis. However, the results of our APPAC trial have now shown that the majority (73%) of patients with uncomplicated acute appendicitis were successfully treated with antibiotics alone. We also showed that none of the patients treated initially with antibiotics and later undergoing appendectomy had major complications or increased morbidity defining antibiotic therapy as a safe first-line treatment. Patients with a complicated acute appendicitis require emergency appendectomy and early identification of these patients is of vital importance. Laparoscopic appendectomy has become the golden standard for appendectomy providing lower morbidity and faster recovery compared with open appendectomy. For patients with uncomplicated acute appendicitis, the time has come to evaluate abandoning routine appendectomy and evaluating the optimal use of antibiotic therapy.

The aim of study is to optimize the antibiotic therapy for uncomplicated acute appendicitis by evaluating the success of treatment in both study groups and by comparing intravenous antibiotic therapy followed by per oral antibiotics with per oral antibiotic monotherapy. The study hypothesis is that broad-spectrum intravenous antibiotics requiring additional hospital resources are not necessary for the treatment of uncomplicated acute appendicitis and that per oral monotherapy is non-inferior to the combination of intravenous and per oral antibiotic therapy. The secondary aim is to evaluate the results of the randomized APPAC trial in a prospective patient cohort by implementing antibiotic therapy as the first-line treatment for uncomplicated acute appendicitis in clinical practice.

Being tested
Ertapenem, Moxifloxacin
Keywords
uncomplicated acute appendicitis, complicated acute appendicitis, antibiotic therapy
Medical subject headings
Appendicitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ErtapenemDrug

    Also called Levofloxacin, Metronidazole

    I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days

  • MoxifloxacinDrug

    P.o. moxifloxacin 400 mg x1 for 7 days

Study groups in NCT03236961
Study groupRoleWhat they receive
Intravenous & per oral antibioticsActive comparatorErtapenem 1 g x 1 for two days i.v. followed by p.o. levofloxacin 500 mg x 1 and metronidazole 500 mg x 3 for 5 days, duration of treatment one week.
Receives: Drug: Ertapenem
Per oral antibioticsActive comparatorMoxifloxacin 400 mg x 1 foe seven days, duration of treatment one week.
Receives: Drug: Moxifloxacin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Treatment success

    The resolution of acute uncomplicated appendicitis with allocated antibiotic treatment. Treatment success is defined as discharge from the hospital without the need for surgical intervention after the primary hospitalisation and no recurrent appendicitis during one-year follow-up.

    Measured: 1 year

Secondary outcomes (6)
  1. Late recurrence of appendicitis after antibiotic treatment

    Recurring appendicitis after primary treatment considered successful, thus recurrence after one year

    Measured: 1 year

  2. Duration of hospital stay

    Hospital stay

    Measured: 1 month

  3. Post-intervention complications

    Complications according to the Clavien-Dindo classification

    Measured: 10 years

  4. VAS pain score (visual analogue score)

    Pain as described with a scale from 0-10

    Measured: 10 years

  5. Sick leave

    Duration of sick leave

    Measured: 1 month

  6. Treatment costs

    Treatment costs including hospital stay costs, medicinal costs, imaging costs, costs to treat possible complications, operative costs

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2017
  2. Study start3 Apr 2017
  3. Primary completion27 Nov 2018
  4. Study completion1 Apr 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
552 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03236961
Sponsor's protocol ID
APPAC II
Acronym
APPACII
Status last verified
Nov 2020
First submitted
26 Jul 2017
Last updated
12 Nov 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Selanne L, Hurme S, Sippola S, Rautio T, Nordstrom P, Rantanen T, Pinta T, Ilves I, Mattila A, Savela EL, Rintala J, Paajanen H, Gronroos J, Haijanen J, Salminen P. Prognostic factors associated with primary non-responsiveness to antibiotics and appendicitis recurrence for CT-diagnosed uncomplicated acute appendicitis: secondary analysis of two randomized clinical trials. Br J Surg. 2025 Jul 3;112(7):znaf143. doi: 10.1093/bjs/znaf143.

    PubMed 40741675
  • Drake FT, Sanchez SE. Acute Appendicitis-What's Old Is New Again. JAMA Surg. 2024 Jul 1;159(7):735-736. doi: 10.1001/jamasurg.2023.5946. No abstract available.

    PubMed 38630482
  • Selanne L, Haijanen J, Sippola S, Hurme S, Rautio T, Nordstrom P, Rantanen T, Pinta T, Ilves I, Mattila A, Rintala J, Marttila H, Merilainen S, Laukkarinen J, Savela EL, Paajanen H, Gronroos J, Salminen P. Three-Year Outcomes of Oral Antibiotics vs Intravenous and Oral Antibiotics for Uncomplicated Acute Appendicitis: A Secondary Analysis of the APPAC II Randomized Clinical Trial. JAMA Surg. 2024 Jul 1;159(7):727-735. doi: 10.1001/jamasurg.2023.5947.

    PubMed 38630471
  • Sippola S, Haijanen J, Gronroos J, Rautio T, Nordstrom P, Rantanen T, Pinta T, Ilves I, Mattila A, Rintala J, Loyttyniemi E, Hurme S, Tammilehto V, Marttila H, Merilainen S, Laukkarinen J, Savela EL, Savolainen H, Sippola T, Aarnio M, Paajanen H, Salminen P. Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial. JAMA. 2021 Jan 26;325(4):353-362. doi: 10.1001/jama.2020.23525.

    PubMed 33427870
  • Haijanen J, Sippola S, Gronroos J, Rautio T, Nordstrom P, Rantanen T, Aarnio M, Ilves I, Hurme S, Marttila H, Virtanen J, Mattila A, Paajanen H, Salminen P; APPAC study group. Optimising the antibiotic treatment of uncomplicated acute appendicitis: a protocol for a multicentre randomised clinical trial (APPAC II trial). BMC Surg. 2018 Dec 17;18(1):117. doi: 10.1186/s12893-018-0451-y.

    PubMed 30558607

Questions about this trial

What is this clinical trial studying?

A study testing Ertapenem and Moxifloxacin in people with Acute Appendicitis, run by Turku University Hospital at 1 site in Finland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 12 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Treatment success (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03236961, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in